CR20170102A - Nuevos activadores de la guanilato ciclasa soluble y su uso - Google Patents
Nuevos activadores de la guanilato ciclasa soluble y su usoInfo
- Publication number
- CR20170102A CR20170102A CR20170102A CR20170102A CR20170102A CR 20170102 A CR20170102 A CR 20170102A CR 20170102 A CR20170102 A CR 20170102A CR 20170102 A CR20170102 A CR 20170102A CR 20170102 A CR20170102 A CR 20170102A
- Authority
- CR
- Costa Rica
- Prior art keywords
- soluble
- guanilate
- cycling
- new activators
- activators
- Prior art date
Links
- 239000012190 activator Substances 0.000 title 1
- 230000001351 cycling effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 1
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 abstract 1
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 abstract 1
- 239000003119 guanylate cyclase activator Substances 0.000 abstract 1
- 230000004410 intraocular pressure Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 241000894007 species Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462052537P | 2014-09-19 | 2014-09-19 | |
| PCT/IB2015/057219 WO2016042536A1 (en) | 2014-09-19 | 2015-09-18 | Novel soluble guanylate cyclase activators and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20170102A true CR20170102A (es) | 2017-07-17 |
Family
ID=54238488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20170102A CR20170102A (es) | 2014-09-19 | 2015-09-18 | Nuevos activadores de la guanilato ciclasa soluble y su uso |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US9938260B2 (OSRAM) |
| EP (1) | EP3194384A1 (OSRAM) |
| JP (3) | JP6678656B2 (OSRAM) |
| KR (1) | KR20170054508A (OSRAM) |
| CN (1) | CN106687456B (OSRAM) |
| AU (1) | AU2015319724B2 (OSRAM) |
| BR (1) | BR112017005660A2 (OSRAM) |
| CA (1) | CA2961745A1 (OSRAM) |
| CL (1) | CL2017000640A1 (OSRAM) |
| CO (1) | CO2017002506A2 (OSRAM) |
| CR (1) | CR20170102A (OSRAM) |
| DO (1) | DOP2017000073A (OSRAM) |
| EA (1) | EA033697B1 (OSRAM) |
| IL (1) | IL251094A0 (OSRAM) |
| MA (1) | MA40583A (OSRAM) |
| MX (1) | MX2017003621A (OSRAM) |
| PE (1) | PE20170937A1 (OSRAM) |
| PH (1) | PH12017500481A1 (OSRAM) |
| SG (1) | SG11201701915TA (OSRAM) |
| WO (1) | WO2016042536A1 (OSRAM) |
| ZA (1) | ZA201701835B (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6479029B2 (ja) | 2014-02-06 | 2019-03-06 | ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物 |
| CA2961745A1 (en) * | 2014-09-19 | 2016-03-24 | Glaxosmithkline Intellectual Property Development Limited | Novel soluble guanylate cyclase activators and their use |
| CR20170100A (es) | 2014-09-19 | 2017-04-24 | Bayer Pharma Aktiengesellchaft | Indazoles sustituidos con bencilo como inhibidores bub1 |
| EP3525778A1 (de) | 2016-10-11 | 2019-08-21 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend sgc aktivatoren und mineralocorticoid-rezeptor-antagonisten |
| WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT |
| EP3498298A1 (en) | 2017-12-15 | 2019-06-19 | Bayer AG | The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi) |
| EP3787610A1 (en) | 2018-04-30 | 2021-03-10 | Bayer Aktiengesellschaft | The use of sgc activators and sgc stimulators for the treatment of cognitive impairment |
| CN112384213A (zh) | 2018-05-15 | 2021-02-19 | 拜耳公司 | 用于治疗与神经纤维敏化有关的疾病的1,3-噻唑-2-基取代的苯甲酰胺 |
| US11508483B2 (en) | 2018-05-30 | 2022-11-22 | Adverio Pharma Gmbh | Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group |
| US20220128561A1 (en) | 2019-01-17 | 2022-04-28 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble gyanylyl cyclase (sgc) |
| EP4536205A1 (en) | 2022-06-09 | 2025-04-16 | Bayer Aktiengesellschaft | Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5602143A (en) | 1994-12-08 | 1997-02-11 | Allergan | Method for reducing intraocular pressure in the mammalian eye by administration of guanylate cyclase inhibitors |
| MX2009004856A (es) | 2006-11-09 | 2009-06-05 | Alcon Res Ltd | Matriz polimerica insoluble en agua para suministro de farmaco. |
| AR069517A1 (es) | 2007-12-03 | 2010-01-27 | Smithkline Beecham Corp | Compuesto del acido fenil metiloxifenil piridinil carboxilico substituido, composiciones farmaceuticas que lo comprenden y su uso para la prepara-cion de un medicamento util para el tratamiento de una enfermedad mediada por la actividad de la enzima sgc |
| WO2010015653A1 (en) * | 2008-08-07 | 2010-02-11 | Smithkline Beecham Corporation | Pyrimidine derivatives as activators of soluble guanylate cyclase |
| WO2010099054A2 (en) * | 2009-02-26 | 2010-09-02 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| DE102009012314A1 (de) * | 2009-03-09 | 2010-09-16 | Bayer Schering Pharma Aktiengesellschaft | Oxo-heterocyclisch substituierte Alkylcarbonsäuren und ihre Verwendung |
| JP5636296B2 (ja) | 2011-01-20 | 2014-12-03 | 公益財団法人微生物化学研究会 | 塩分含有有機廃液処理剤、並びに、塩分濃度低下剤、塩分含有有機廃液の処理方法、及び包括固定担体 |
| CA2961745A1 (en) * | 2014-09-19 | 2016-03-24 | Glaxosmithkline Intellectual Property Development Limited | Novel soluble guanylate cyclase activators and their use |
-
2015
- 2015-09-18 CA CA2961745A patent/CA2961745A1/en not_active Abandoned
- 2015-09-18 SG SG11201701915TA patent/SG11201701915TA/en unknown
- 2015-09-18 PE PE2017000478A patent/PE20170937A1/es unknown
- 2015-09-18 KR KR1020177010181A patent/KR20170054508A/ko not_active Ceased
- 2015-09-18 WO PCT/IB2015/057219 patent/WO2016042536A1/en not_active Ceased
- 2015-09-18 US US15/509,895 patent/US9938260B2/en active Active
- 2015-09-18 AU AU2015319724A patent/AU2015319724B2/en active Active
- 2015-09-18 MA MA040583A patent/MA40583A/fr unknown
- 2015-09-18 CR CR20170102A patent/CR20170102A/es unknown
- 2015-09-18 JP JP2017515074A patent/JP6678656B2/ja active Active
- 2015-09-18 MX MX2017003621A patent/MX2017003621A/es unknown
- 2015-09-18 CN CN201580050717.XA patent/CN106687456B/zh active Active
- 2015-09-18 BR BR112017005660A patent/BR112017005660A2/pt not_active Application Discontinuation
- 2015-09-18 EP EP15772026.9A patent/EP3194384A1/en not_active Withdrawn
- 2015-09-18 EA EA201790655A patent/EA033697B1/ru not_active IP Right Cessation
-
2017
- 2017-03-12 IL IL251094A patent/IL251094A0/en unknown
- 2017-03-14 ZA ZA2017/01835A patent/ZA201701835B/en unknown
- 2017-03-14 PH PH12017500481A patent/PH12017500481A1/en unknown
- 2017-03-16 DO DO2017000073A patent/DOP2017000073A/es unknown
- 2017-03-16 CL CL2017000640A patent/CL2017000640A1/es unknown
- 2017-03-16 CO CONC2017/0002506A patent/CO2017002506A2/es unknown
-
2018
- 2018-03-05 US US15/911,797 patent/US10472350B2/en active Active
-
2020
- 2020-03-02 JP JP2020035272A patent/JP6908747B2/ja active Active
-
2021
- 2021-06-30 JP JP2021109106A patent/JP2021155450A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015319724B2 (en) | 2018-05-10 |
| US20170305888A1 (en) | 2017-10-26 |
| CA2961745A1 (en) | 2016-03-24 |
| CL2017000640A1 (es) | 2017-10-06 |
| MA40583A (fr) | 2016-03-24 |
| PE20170937A1 (es) | 2017-07-13 |
| JP2021155450A (ja) | 2021-10-07 |
| BR112017005660A2 (pt) | 2017-12-19 |
| JP2017527602A (ja) | 2017-09-21 |
| US9938260B2 (en) | 2018-04-10 |
| EA201790655A1 (ru) | 2017-08-31 |
| JP6908747B2 (ja) | 2021-07-28 |
| ZA201701835B (en) | 2018-12-19 |
| KR20170054508A (ko) | 2017-05-17 |
| US20180194756A1 (en) | 2018-07-12 |
| EP3194384A1 (en) | 2017-07-26 |
| AU2015319724A1 (en) | 2017-04-06 |
| US10472350B2 (en) | 2019-11-12 |
| JP6678656B2 (ja) | 2020-04-08 |
| IL251094A0 (en) | 2017-04-30 |
| PH12017500481A1 (en) | 2017-08-07 |
| WO2016042536A1 (en) | 2016-03-24 |
| CN106687456B (zh) | 2019-12-03 |
| CN106687456A (zh) | 2017-05-17 |
| JP2020105189A (ja) | 2020-07-09 |
| DOP2017000073A (es) | 2017-04-16 |
| EA033697B1 (ru) | 2019-11-18 |
| SG11201701915TA (en) | 2017-04-27 |
| MX2017003621A (es) | 2017-07-14 |
| CO2017002506A2 (es) | 2017-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2017000073A (es) | Nuevos activadores de la guanilato ciclasa soluble y su uso | |
| DOP2019000005A (es) | 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2 | |
| CY1123953T1 (el) | Καθυστερημενης απελευθερωσης συνθεσεις λινακλοτιδης | |
| ECSP17078433A (es) | Composiciones de ácido obeticólico y métodos de uso | |
| NI201700096A (es) | Derivados de 4h-pirrol[3, 2-c]piridin-4-ona | |
| ECSP17081744A (es) | Nuevos derivados hidroxiéster,un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| SV2018005610A (es) | Derivados de oxopiridina sustituidos | |
| CL2017001923A1 (es) | Derivados de 9h-pirrolo-dipiridina | |
| SV2018005760A (es) | Derivados de aminotiazol utiles como agentes antiviricos | |
| MX2020002123A (es) | Sales de ribociclib y formas en estado sólido de las mismas. | |
| MX2018002416A (es) | Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos. | |
| UY35997A (es) | Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| MX2017013137A (es) | Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas. | |
| DOP2016000297A (es) | Composiciones farmacéuticas útiles para tratar enfermedades infecciosas | |
| CR20170090A (es) | Derivados de terahidroquinolina como inhibidores del bromodominio | |
| MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
| MX2018013701A (es) | Derivados de piridinilo, composiciones farmaceuticas y sus usos como inhibidores aoc3. | |
| CO2017002963A2 (es) | Espiro-tiazolonas | |
| CR20140051A (es) | Compuestos de tiazol y oxazol de bencen-sulfonamida | |
| UY36958A (es) | Compuestos para administración intracelular | |
| MX380683B (es) | Lisobactina para su uso en el tratamiento de la mastitis bovina. | |
| MX385113B (es) | Uso de hidróxido de potasio en el tratamiento de la queratosis actínica. | |
| GT201500116A (es) | Mètodo para preparar derivados de feniloximetil-nitro-imidazol y su uso del mismo |